A Randomised, Double-Blind, Placebo Controlled Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs PBT 2 (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Acronyms IMAGINE
- Sponsors Prana Biotechnology
- 17 Jul 2014 According to the Prana Biotechnology media release, data from this trial was presented at the Alzheimer's Association International Conference 12-14 Jul 2014.
- 31 Mar 2014 Status changed from active, no longer recruiting to completed, as reported in a Prana Biotechnology media release.
- 31 Mar 2014 Top-line results reported in a Prana Biotechnology media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History